FAQ
BPC-157 TB-500 FAQ: The Wolverine Blend, Answered
Twenty-five questions on the two-peptide blend — definition, mechanism, angiogenesis, dosage context, safety, and regulatory status — each answered directly from the cited literature.
Definition and identity
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein [1]; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 [8]. The "Wolverine" blend pairs the two as a research-community tissue-repair stack — not a single chemical entity, and not an approved product.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or standardized ratio, and is not an approved product anywhere [8].
What is the BPC-157 and TB-500 blend used for in research?
Preclinical, mostly rodent research on the two constituents covers tendon, ligament, muscle, and bone repair, wound and soft-tissue healing, and angiogenesis [1][4]. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study [9].
What is the difference between BPC-157 and TB-500?
They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein acting via VEGFR2/nitric-oxide and growth-hormone-receptor pathways [1][2]; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting by sequestering G-actin [3]. Different sequences, sizes, and mechanisms.
Mechanism and combination
How does BPC-157 work compared to TB-500?
BPC-157 supplies a local cytoprotective and pro-angiogenic signal — VEGFR2-Akt-eNOS up-regulation, nitric-oxide modulation, and growth-hormone-receptor sensitization of tendon fibroblasts [2][5][6]. TB-500 supplies an intracellular actin-sequestration signal: 1:1 G-actin binding via the LKKTETQ motif that regulates cell migration [3]. They act through complementary but largely non-overlapping pathways.
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500 is the Ac-LKKTETQ fragment of Thymosin Beta-4. X-ray crystallography established that Thymosin Beta-4 forms a 1:1 complex with monomeric G-actin and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization [3].
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157's local angiogenic and cytoprotective signal is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of tissue repair [2][4]. Critically, no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint for the two given together [9].
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
In preclinical models, yes — by separate routes. BPC-157 up-regulates VEGFR2 and promotes VEGFR2 internalization with downstream Akt-eNOS signaling (increased vessel density, faster blood-flow recovery in ischemic rat muscle) [2]; Thymosin Beta-4 (TB-500's parent) promotes endothelial-migration angiogenesis [4]. No controlled combination study has measured their combined angiogenic effect [9].
Do BPC-157 and TB-500 act through the same pathway?
No. BPC-157 acts on VEGFR2-Akt-eNOS / nitric-oxide and growth-hormone-receptor signaling [2][5]; TB-500 acts on the cytoskeleton by sequestering monomeric G-actin [3]. The "synergy" rationale rests on these being complementary, non-overlapping mechanisms — a theoretical extrapolation, not a demonstrated combination finding [9].
Evidence and efficacy
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 (36 studies, only one human, "no clinical safety data") makes no mention of TB-500 or combination use [9]. "Synergy" is an extrapolation from each peptide's separate mechanism.
Are there human clinical trials on the BPC-157 + TB-500 combination?
None. There are no controlled clinical trials of the BPC-157 + TB-500 combination for any indication. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies; "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide [9].
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
In animal models, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures and enhanced tendon-fibroblast outgrowth [1][7]; Thymosin Beta-4 improved ligament healing in rats [4]. These are preclinical, single-compound results, not human or combination evidence.
Does BPC-157 and TB-500 help muscle tears and recovery?
Preclinical studies report BPC-157 aiding muscle and myotendinous-junction repair and Thymosin Beta-4 acting as a myoblast chemoattractant [1][4]; however, a six-month Thymosin Beta-4 mdx-mouse study increased regenerating fibers but produced no gain in strength [4]. Findings are animal-model and single-compound.
Does the BPC-157 TB-500 blend help wound healing?
In animal wound models, Thymosin Beta-4 (TB-500's parent) increased re-epithelialization, contraction, collagen deposition, and angiogenesis [4], and BPC-157 shows multi-tissue cytoprotection [1]. These are preclinical, single-compound results; the blend itself has no controlled wound-healing trial.
Dosage and handling
What is the half-life of BPC-157 and TB-500?
No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study [1]; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide [12].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [8]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. This is research-handling context, not a human-use instruction.
How often should you inject BPC-157 and TB-500?
There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing — for example, Thymosin Beta-4 at 150 microg twice weekly intraperitoneally for six months in one model [4]. Community "loading then maintenance" protocols have no controlled-trial basis.
How do you cycle BPC-157 and TB-500?
No validated cycle exists. Community "loading then maintenance" blend protocols and fixed-ratio vials (e.g. 10 mg + 10 mg) have no basis in controlled human trials and should not be presented as validated dosing [8][9]. Underlying study durations vary widely by model.
Side Effects and Safety Signals in Research
What are the side effects of BPC-157 and TB-500?
Long-term human safety is unknown for both constituents and the blend. The principal documented concern is a tumor signal: Thymosin Beta-4 is implicated in metastasis and tumor angiogenesis, so the same pro-angiogenic, pro-migratory properties that aid repair could theoretically support tumor progression [4]. Combining two unapproved peptides doubles the uncertainty.
TB-500 and the Tumor-Angiogenesis Question
Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis in tumor models; this is a theoretical safety consideration, not a demonstrated cancer-causing effect of TB-500 in humans [4]. No human data establish either safety or harm for the TB-500 fragment in this respect.
Is TB-500 bad for your heart?
Human intravenous full-length Thymosin Beta-4 was well tolerated to 1260 mg with no dose-limiting toxicities in a Phase 1 study, and a 2021 first-in-human study reported only mild-to-moderate adverse events [12]. However, an mdx-mouse study showed no cardiac-function improvement [4], and no controlled cardiac-safety data exist for the TB-500 heptapeptide or the blend.
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis in tumor models, a theoretical safety consideration rather than a demonstrated human effect [4]. No human data establish either safety or harm for the TB-500 fragment, and the blend has no human safety record at all [9].
Legal and regulatory status
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither constituent is FDA-approved and the blend has no approved indication. FDA placed both BPC-157 and TB-500 in 503A Category 2 — bulk substances identified as raising significant safety risks — effective the September 29, 2023 list update [13]. Both are WADA-prohibited: BPC-157 under the S0 non-approved-substances category, and TB-500/Thymosin Beta-4 under prohibited peptide/growth-factor categories.
Is Wolverine legal?
Neither constituent is an FDA-approved drug, and the blend has no approved indication. Both are 503A Category 2 bulk substances, so compounding-pharmacy access is currently restricted; both are on the scheduled July 23-24, 2026 FDA advisory-committee agenda as candidates for the 503A bulks list — a scheduled discussion, not a decision [13][15].
Can you get BPC-157 from a compounding pharmacy?
BPC-157 is in 503A Category 2, which is outside FDA's enforcement-discretion policy, so routine compounding-pharmacy access is restricted while that status stands [13][14]. A lawful compounded preparation requires a licensed-prescriber evaluation, a valid patient-specific prescription, and an eligible ingredient — and Category 2 status is the binding constraint on eligibility today [16].
What is the FDA 503A status of Wolverine?
Both constituents are 503A Category 2 bulk drug substances, effective the September 29, 2023 update to FDA's nominated-substances list [13]. Category 2 means FDA identified significant safety risks and does not extend enforcement-discretion to the substance [14]. Both BPC-157 and TB-500 are on the scheduled July 23-24, 2026 advisory-committee agenda as candidates for the 503A bulks list — a scheduled evaluation, not a change in current status [15].